State Street Corp Adial Pharmaceuticals, Inc. Transaction History

State Street Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	BUY	$45.0 - $69.0 $99,000 - $151,800	2,200 Added 4.39%	52,354 $105,000
Q3 2021 Nov 15, 2021	BUY	$57.75 - $116.75 $69,300 - $140,100	1,200 Added 2.45%	50,154 $215,000
Q2 2021 Aug 16, 2021	BUY	$50.5 - $78.25 $2.47 Million - $3.83 Million	48,954 New	48,954 $125,000

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $27.1M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.